{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T22:26:51Z","timestamp":1747175211839,"version":"3.40.5"},"reference-count":66,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1053\/j.seminhematol.2024.10.002","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T22:13:40Z","timestamp":1729289620000},"page":"3-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Smoldering multiple myeloma: Integrating biology and risk into management"],"prefix":"10.1053","volume":"62","author":[{"given":"Roshani","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5152-5956","authenticated-orcid":false,"given":"Elizabeth","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhav","family":"Dhodapkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"24","key":"10.1053\/j.seminhematol.2024.10.002_bib0001","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma","volume":"302","author":"Kyle","year":"1980","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.10.002_bib0002","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/blood.V56.3.521.521","article-title":"Localized and indolent myeloma","volume":"56","author":"Alexanian","year":"1980","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.10.002_bib0003","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/leu.2012.309","article-title":"Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease","volume":"27","author":"Kastritis","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.10.002_bib0004","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMc1106428","article-title":"Diagnosis of smoldering multiple myeloma","volume":"365","author":"Rajkumar","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.10.002_bib0005","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/leu.2012.296","article-title":"Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma","volume":"27","author":"Larsen","year":"2013","journal-title":"Leukemia"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.10.002_bib0006","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"28","author":"Hillengass","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.10.002_bib0007","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1038\/leu.2014.230","article-title":"The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma","volume":"28","author":"Kastritis","year":"2014","journal-title":"Leukemia"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.10.002_bib0008","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1053\/j.seminhematol.2024.10.002_bib0009","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"22","key":"10.1053\/j.seminhematol.2024.10.002_bib0010","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A monoclonal gammopathy precedes multiple myeloma in most patients","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"issue":"25","key":"10.1053\/j.seminhematol.2024.10.002_bib0011","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.10.002_bib0012","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.10.002_bib0013","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.3390\/cells10061360","article-title":"Role of 1q21 in multiple myeloma: from pathogenesis to possible therapeutic targets","volume":"10","author":"Burroughs Garcia","year":"2021","journal-title":"Cells"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.10.002_bib0014","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood.V100.4.1417.h81602001417_1417_1424","article-title":"Genomic abnormalities in monoclonal gammopathy of undetermined significance","volume":"100","author":"Fonseca","year":"2002","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.10.002_bib0015","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood.2024024299","article-title":"The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma","volume":"144","author":"Cirrincione","year":"2024","journal-title":"Blood"},{"issue":"21","key":"10.1053\/j.seminhematol.2024.10.002_bib0016","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.20.00437","article-title":"Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression","volume":"38","author":"Bustoros","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.10.002_bib0017","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/nm.4202","article-title":"Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice","volume":"22","author":"Das","year":"2016","journal-title":"Nat Med"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.10.002_bib0018","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1084\/jem.20031030","article-title":"Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy","volume":"198","author":"Dhodapkar","year":"2003","journal-title":"J Exp Med"},{"key":"10.1053\/j.seminhematol.2024.10.002_sbref0019","article-title":"Dissecting molecular mechanisms of immune microenvironment dysfunction in multiple myeloma and precursor conditions","volume":"9","author":"Moscvin","year":"2023","journal-title":"J Cancer Metastasis Treat"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.10.002_bib0020","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat Cancer"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.10.002_sbref0021","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127807","article-title":"Early alterations in stem-like\/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy","volume":"5","author":"Bailur","year":"2019","journal-title":"JCI Insight"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.10.002_bib0022","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.hoc.2023.12.011","article-title":"Immune-pathogenesis of myeloma","volume":"38","author":"Dhodapkar","year":"2024","journal-title":"Hematol Oncol Clin North Am"},{"issue":"15","key":"10.1053\/j.seminhematol.2024.10.002_sbref0023","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167629","article-title":"Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy","volume":"133","author":"Robinson","year":"2023","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.10.002_bib0024","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.10.002_bib0025","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.10.002_bib0026","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.10.002_bib0027","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.10.002_sbref0028","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051223","article-title":"Treatment of smoldering multiple myeloma: ready for prime time?","volume":"12","author":"Kim","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"20","key":"10.1053\/j.seminhematol.2024.10.002_bib0029","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","article-title":"Smoldering multiple myeloma","volume":"125","author":"Rajkumar","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.10.002_bib0030","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1046\/j.1365-2141.2003.04654.x","article-title":"Smoldering multiple myeloma: natural history and recognition of an evolving type","volume":"123","author":"Rosinol","year":"2003","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.10.002_bib0031","doi-asserted-by":"crossref","first-page":"300","DOI":"10.4065\/mcp.2009.0653","article-title":"Plasma cell labeling index in the evaluation of smoldering (asymptomatic) multiple myeloma","volume":"85","author":"Madan","year":"2010","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.10.002_sbref0032","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13050961","article-title":"Analyzing longitudinal wb-MRI data and clinical course in a cohort of former smoldering multiple myeloma patients: connections between MRI findings and clinical progression patterns","volume":"13","author":"Wennmann","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.10.002_bib0033","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/leu.2012.237","article-title":"High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma","volume":"27","author":"Bianchi","year":"2013","journal-title":"Leukemia"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.10.002_bib0034","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S2352-3026(22)00386-6","article-title":"Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study","volume":"10","author":"Cowan","year":"2023","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.10.002_bib0035","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.3109\/10428194.2013.764419","article-title":"Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study","volume":"54","author":"Cherry","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.002_bib0036","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1001\/jamaoncol.2020.5585","article-title":"Assessment of discordance among smoldering multiple myeloma risk models","volume":"7","author":"Hill","year":"2021","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.10.002_bib0037","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1002\/hem3.76","article-title":"The evolving pattern of the monoclonal protein improves the IMWG 2\/20\/20 classification for patients with smoldering multiple myeloma","volume":"8","author":"de Daniel","year":"2024","journal-title":"Hemasphere"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.002_bib0038","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2013-07-515239","article-title":"Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)","volume":"123","author":"Dhodapkar","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.002_bib0039","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41408-024-01024-8","article-title":"Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing","volume":"14","author":"Li","year":"2024","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.002_bib0040","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41408-024-01024-8","article-title":"Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing","volume":"14","author":"Li","year":"2024","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.002_bib0041","doi-asserted-by":"crossref","first-page":"7040","DOI":"10.1038\/s41467-022-33944-z","article-title":"Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis","volume":"13","author":"Boiarsky","year":"2022","journal-title":"Nat Commun"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.10.002_bib0042","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0009-9260(67)80010-2","article-title":"The radiological demonstration of osseous metastases. Experimental observations","volume":"18","author":"Edelstyn","year":"1967","journal-title":"Clin Radiol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.002_bib0043","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00330-007-0738-3","article-title":"Comparison of whole-body 64-slice multidetector computed tomography and conventional radiography in staging of multiple myeloma","volume":"18","author":"Kr\u00f6pil","year":"2008","journal-title":"Eur Radiol"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.10.002_bib0044","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1148\/radiology.154.2.3966137","article-title":"Multiple myeloma: evaluation by CT","volume":"154","author":"Schreiman","year":"1985","journal-title":"Radiology"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.10.002_bib0045","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.ejrad.2014.02.008","article-title":"Sensitivity of whole-body CT and MRI versus projection radiography in the detection of osteolyses in patients with monoclonal plasma cell disease","volume":"83","author":"Wolf","year":"2014","journal-title":"Eur J Radiol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.002_bib0046","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/bjh.17088","article-title":"Diagnostic performance of (18) F-FDG-PET\/CT compared to standard skeletal survey for detecting bone destruction in smouldering multiple myeloma: time to move forward","volume":"193","author":"Hill","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2024.10.002_bib0047","first-page":"e407","volume":"36","author":"Terpos","year":"2016"},{"key":"10.1053\/j.seminhematol.2024.10.002_bib0048","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2020-136185","article-title":"Evaluation of whole-body MRI (WB-MRI) in smoldering multiple myeloma (SMM)","volume":"136","author":"Elizabeth Hill","year":"2020","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.10.002_bib0049","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3109\/10428194.2012.740559","article-title":"Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging \u201cearly myeloma","volume":"54","author":"Hillengass","year":"2013","journal-title":"Leuke Lymph"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.10.002_bib0050","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0609.1993.tb00148.x","article-title":"Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I\u2013a randomized study. Myeloma Group of Western Sweden","volume":"50","author":"Hjorth","year":"1993","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.10.002_bib0051","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/sj.leu.2402866","article-title":"Thalidomide as initial therapy for early-stage myeloma","volume":"17","author":"Rajkumar","year":"2003","journal-title":"Leukemia"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.10.002_bib0052","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood-2008-06-164228","article-title":"Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease","volume":"112","author":"Barlogie","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.10.002_bib0053","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.10.002_bib0054","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","article-title":"Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial","volume":"17","author":"Mateos","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2024.10.002_bib0055","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ejca.2022.07.030","article-title":"Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: a randomized, open-label study","volume":"174","author":"Mateos","year":"2022","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.10.002_bib0056","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41375-020-0718-z","article-title":"Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)","volume":"34","author":"Landgren","year":"2020","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2024.10.002_bib0057","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1182\/blood-2022-159606","article-title":"Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)","volume":"140","author":"Maria-Victoria Mateos","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.10.002_bib0058","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1182\/blood-2022-168930","article-title":"Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial","volume":"140","author":"Kumar","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.10.002_bib0059","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1001\/jamaoncol.2021.3971","article-title":"Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial","volume":"7","author":"Kazandjian","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.seminhematol.2024.10.002_bib0060","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1182\/blood-2023-177954","article-title":"Immuno-PRISM: a randomized phase II platform study of bispecific antibodies in high-risk smoldering myeloma","volume":"142","author":"Nadeem","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.10.002_bib0061","unstructured":"Bar, N. Daratumumab to enhance therapeutic effectiveness of revlimid in smoldering myeloma (DETER-SMM)."},{"key":"10.1053\/j.seminhematol.2024.10.002_bib0062","doi-asserted-by":"crossref","first-page":"7317","DOI":"10.1182\/blood-2022-157302","article-title":"Sandrine mac\u00e9, mony morisse, irene ghobrial, isatuximab in combination with lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma: updated safety run-in results from the randomized phase 3 ithaca study","volume":"140","author":"Mateos","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.10.002_sbref0063","article-title":"Long-term follow-up defines the population that benefits from early interception in a high-risk smoldering multiple myeloma clinical trial using the combination of ixazomib, lenalidomide, and dexamethasone","author":"Nadeem","year":"2024","journal-title":"medRxiv"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.002_bib0064","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-024-01053-3","article-title":"The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression","volume":"14","author":"Medina-Herrera","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminhematol.2024.10.002_sbref0065","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-24-0210","article-title":"Genomic profiling to contextualize the results of intervention for smoldering multiple myeloma","author":"Kazandjian","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.002_bib0066","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41408-024-00980-5","article-title":"Mode of progression in smoldering multiple myeloma: a study of 406 patients","volume":"14","author":"Abdallah","year":"2024","journal-title":"Blood Cancer J"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324001124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324001124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T14:07:46Z","timestamp":1741961266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196324001124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0037196324001124"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.10.002","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Smoldering multiple myeloma: Integrating biology and risk into management","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}